Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
BMC Medical Education
|
October 20, 2007
Newly qualified doctors' views about whether their medical school had trained them well: questionnaire surveys
Judith Cave, Michael Goldacre, Trevor Lambert, et al.
BMJ Open
|
August 26, 2019
The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis
Salma Naheed, Chloe Holden, Lulu Tanno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2008
Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma
Anna Cassoni, Usman Ali, Judith Cave, et al.
Pancreas
|
October 7, 2017
Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors
Sebastian Richards-Taylor, Charles Tilley, Eleanor Jaynes, et al.
Journal of Clinical Pathology
|
December 19, 2015
The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis
Sebastian Richards-Taylor, Sean M Ewings, Eleanor Jaynes, et al.
Chemotherapy
|
August 22, 2012
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer
Simon J Crabb, Jennifer Bradbury, Luke Nolan, et al.
Postgraduate Medical Journal
|
February 3, 2007
DR WHO: a workshop for house officer preparation
Judith Cave, Deirdre Wallace, Glenda Baillie, et al.
BMJ Open
|
March 4, 2022
Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
Salma Naheed, Chloe Holden, Lulu Tanno, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Edurne Arriola, Matthew Wheater, Ian Galea, et al.
Expert Review of Molecular Diagnostics
|
March 23, 2019
Recent advances in the molecular landscape of lung neuroendocrine tumors
Giuseppe Pelosi, Fabrizio Bianchi, Paul Hofman, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
BMC Medical Education
|
October 20, 2007
Newly qualified doctors' views about whether their medical school had trained them well: questionnaire surveys
Judith Cave, Michael Goldacre, Trevor Lambert, et al.
BMJ Open
|
August 26, 2019
The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis
Salma Naheed, Chloe Holden, Lulu Tanno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2008
Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma
Anna Cassoni, Usman Ali, Judith Cave, et al.
Pancreas
|
October 7, 2017
Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors
Sebastian Richards-Taylor, Charles Tilley, Eleanor Jaynes, et al.
Journal of Clinical Pathology
|
December 19, 2015
The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis
Sebastian Richards-Taylor, Sean M Ewings, Eleanor Jaynes, et al.
Chemotherapy
|
August 22, 2012
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer
Simon J Crabb, Jennifer Bradbury, Luke Nolan, et al.
Postgraduate Medical Journal
|
February 3, 2007
DR WHO: a workshop for house officer preparation
Judith Cave, Deirdre Wallace, Glenda Baillie, et al.
BMJ Open
|
March 4, 2022
Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
Salma Naheed, Chloe Holden, Lulu Tanno, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Edurne Arriola, Matthew Wheater, Ian Galea, et al.
Expert Review of Molecular Diagnostics
|
March 23, 2019
Recent advances in the molecular landscape of lung neuroendocrine tumors
Giuseppe Pelosi, Fabrizio Bianchi, Paul Hofman, et al.
Page
of 4